FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2197316641> ?p ?o ?g. }

• W2197316641 abstract "Since the original description of proinflammatory cytokines in patients with heart failure in 1990 (1), there has been enormous interest in the role that these molecules play in regulating cardiac structure and function, particularly with regard to their potential role in disease progression in heart failure. The recognition of the important pathophysiological consequences of sustained expression of proinflammatory mediators in pre-clinical and clinical heart failure models culminated in a series of multicenter clinical trials that utilized “targeted” approaches to neutralize tumor necrosis factor in patients with moderate to advanced heart failure. Unfortunately, these targeted approaches were negative with respect to the primary end points of the trial, and in some patients resulted in worsening heart failure and/or death (2, 3). Collectively, these two clinical trials have had a chilling effect on further attempts to target inflammation in heart failure, and have raised a number of nagging questions about what role, if any, that proinflammatory cytokines play in the pathogenesis of heart failure, Germane to the present discussion, in the current issue of the Journal Deftereos and colleagues report their findings on a six month course of treatment with colchicine in patients with heart failure with a depressed ejection fraction ≤ 40% (4). The rationale for this study was that colchicine has been known to exert anti-inflammatory effects in various cardiovascular settings (reviewed in reference 5), and might therefore also be useful in treating heart failure patients. Patients with stable heart failure on appropriate medical therapy were randomized to receive colchicine (0.5mg twice daily) or placebo for six months. The primary end point of the study, for which the trial was powered adequately, was the proportion of patients achieving at least a one grade improvement in the New York Heart Association functional class. Secondary end points, for which the trial was not adequately powered for, included a composite of death and hospitalization for heart failure, the change in left ventricular and end diastolic-diameter (2-D echocardiography), change in left ventricular ejection fraction and change in treadmill exercise time. In comparison to patients who were treated with conventional heart failure therapy, the authors observed that 11% of the control subjects had an improvement in New York Heart Association class whereas 14% of patients in the colchicine group experienced an improvement in New York Heart Association classification (p=0.36). Moreover, the composite of death or hospitalization for heart failure was 9.4% in the control group compared with 10.1% in the colchicine group (p=0.84). The changes in treadmill exercise time were insignificant in the control and treatment arms. Importantly the magnitude of the decrease in circulating levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were both significantly reduced in the colchicine treated group when compared to placebo. There was ~ a two-fold (p = 0.007) increase in gastrointestinal symptoms in the treatment group, whereas there were no serious complications in terms of renal and/or hepatic function. The authors conclude that anti-inflammatory treatment with colchicine in patients with stable heart failure, although effective in reducing inflammation biomarker levels, did not significantly affect functional class or the likelihood of death or hospitalization. Given the negative outcome of previous trials using anti-inflammatory agents in heart failure, the current study raises further questions about targeting of inflammation in this patient population." @default.
• W2197316641 created "2016-06-24" @default.
• W2197316641 creator A5076497318 @default.
• W2197316641 date "2014-04-01" @default.
• W2197316641 modified "2023-09-28" @default.
• W2197316641 title "Colchicine and the Failing Heart" @default.
• W2197316641 cites W1484709609 @default.
• W2197316641 cites W1533060560 @default.
• W2197316641 cites W2009508503 @default.
• W2197316641 cites W2064157036 @default.
• W2197316641 cites W2147155927 @default.
• W2197316641 cites W2159513257 @default.
• W2197316641 cites W2324476825 @default.
• W2197316641 cites W85445957 @default.
• W2197316641 doi "https://doi.org/10.1016/j.jchf.2014.02.001" @default.
• W2197316641 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4538941" @default.
• W2197316641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24720920" @default.
• W2197316641 hasPublicationYear "2014" @default.
• W2197316641 type Work @default.
• W2197316641 sameAs 2197316641 @default.
• W2197316641 citedByCount "4" @default.
• W2197316641 countsByYear W21973166412014 @default.
• W2197316641 countsByYear W21973166412016 @default.
• W2197316641 countsByYear W21973166412018 @default.
• W2197316641 countsByYear W21973166412023 @default.
• W2197316641 crossrefType "journal-article" @default.
• W2197316641 hasAuthorship W2197316641A5076497318 @default.
• W2197316641 hasBestOaLocation W21973166411 @default.
• W2197316641 hasConcept C126322002 @default.
• W2197316641 hasConcept C151730666 @default.
• W2197316641 hasConcept C164027704 @default.
• W2197316641 hasConcept C164705383 @default.
• W2197316641 hasConcept C177713679 @default.
• W2197316641 hasConcept C2776636253 @default.
• W2197316641 hasConcept C2776914184 @default.
• W2197316641 hasConcept C2778198053 @default.
• W2197316641 hasConcept C2779343474 @default.
• W2197316641 hasConcept C535046627 @default.
• W2197316641 hasConcept C71924100 @default.
• W2197316641 hasConcept C78085059 @default.
• W2197316641 hasConcept C86803240 @default.
• W2197316641 hasConceptScore W2197316641C126322002 @default.
• W2197316641 hasConceptScore W2197316641C151730666 @default.
• W2197316641 hasConceptScore W2197316641C164027704 @default.
• W2197316641 hasConceptScore W2197316641C164705383 @default.
• W2197316641 hasConceptScore W2197316641C177713679 @default.
• W2197316641 hasConceptScore W2197316641C2776636253 @default.
• W2197316641 hasConceptScore W2197316641C2776914184 @default.
• W2197316641 hasConceptScore W2197316641C2778198053 @default.
• W2197316641 hasConceptScore W2197316641C2779343474 @default.
• W2197316641 hasConceptScore W2197316641C535046627 @default.
• W2197316641 hasConceptScore W2197316641C71924100 @default.
• W2197316641 hasConceptScore W2197316641C78085059 @default.
• W2197316641 hasConceptScore W2197316641C86803240 @default.
• W2197316641 hasLocation W21973166411 @default.
• W2197316641 hasLocation W21973166412 @default.
• W2197316641 hasLocation W21973166413 @default.
• W2197316641 hasLocation W21973166414 @default.
• W2197316641 hasOpenAccess W2197316641 @default.
• W2197316641 hasPrimaryLocation W21973166411 @default.
• W2197316641 hasRelatedWork W18498402 @default.
• W2197316641 hasRelatedWork W1971512207 @default.
• W2197316641 hasRelatedWork W1978655859 @default.
• W2197316641 hasRelatedWork W1995135253 @default.
• W2197316641 hasRelatedWork W2009886734 @default.
• W2197316641 hasRelatedWork W2056838448 @default.
• W2197316641 hasRelatedWork W2056861573 @default.
• W2197316641 hasRelatedWork W2068833386 @default.
• W2197316641 hasRelatedWork W2124413154 @default.
• W2197316641 hasRelatedWork W2124463632 @default.
• W2197316641 hasRelatedWork W2141808788 @default.
• W2197316641 hasRelatedWork W2320186017 @default.
• W2197316641 hasRelatedWork W2328830275 @default.
• W2197316641 hasRelatedWork W2335312575 @default.
• W2197316641 hasRelatedWork W2395951484 @default.
• W2197316641 hasRelatedWork W2411389830 @default.
• W2197316641 hasRelatedWork W2411728736 @default.
• W2197316641 hasRelatedWork W2466232502 @default.
• W2197316641 hasRelatedWork W2581076299 @default.
• W2197316641 hasRelatedWork W2592433293 @default.
• W2197316641 isParatext "false" @default.
• W2197316641 isRetracted "false" @default.
• W2197316641 magId "2197316641" @default.
• W2197316641 workType "article" @default.